NGeneBio said on Thursday that it launched its next-generation sequence (NGS)-based breast cancer diagnostic service in a newly installed inspection laboratory of a Thai consignment inspection agency, MP Group.

NGeneBio CEO NGeneBio CEO Choi Dae-chul (left) and MP Group Chairman Rittichai Srivijarn pose for a picture at the launch ceremony for NGeneBio’s NGS-based breast cancer diagnostic service in Thailand.
NGeneBio CEO NGeneBio CEO Choi Dae-chul (left) and MP Group Chairman Rittichai Srivijarn pose for a picture at the launch ceremony for NGeneBio’s NGS-based breast cancer diagnostic service in Thailand.

The MP Group is Thailand's leading consignment inspection agency and distributor specializing in medical devices. They held a grand opening event on Monday to launch its first NGS service. 

NGeneBio representatives also attended and presented the necessity of NGS precision diagnosis and introduced NGeneBio products.

NGeneBio plans to provide its NGS-based precision diagnosis services to medium and large hospitals, government-affiliated medical institutions, health centers, and the general public through MP Group's newly opened laboratory.

The service launched by the MP Group laboratory uses NGeneBio’s BRCAaccuTest PLUS test to identify the BRCA gene which is related to breast cancer and ovarian cancer. The BRCA test service analyzes breast cancer 1 (BRCA 1) and breast cancer 2 (BRCA2) gene mutation screening, an individual's innate breast cancer, ovarian cancer risk, and family history to identify genetic characteristics, and generates personalized gene reports.

"BRCAaccuTest PLUS is a medical device certified by FDA Thailand and can be used not only as a diagnostic test for breast cancer target treatment but also as a test for mutation screening of BRCA1/2 genes," MP Group Chairman Rittichai Srivijarn said.

"Thailand has the largest medical device market among ASEAN countries due to the government's active support and investment in healthcare," said NGeneBio CEO Choi Dae-chul. "As we have been asked to cooperate in research on genome projects, we will make efforts to expand the Thai market and lead the NGS precision diagnosis market in Southeast Asia."

Copyright © KBR Unauthorized reproduction, redistribution prohibited